Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study
Brown JR, Barrientos JC, Barr PM, et al.
Key Points:
chemoimmunotherapy regimen of bendamustine (B) and rituximab (R) (BR) active and well-established treatment regimen in Relapsed/Refractory CLL patients
Final results of this phase IB study showed that ibrutinib in combination with BR tolerable and highly active in patients with Relapsed/Refractory CLL/SLL
ORR substantially high at 93% and independent of high-risk features
Phase III trial of regimen in same patient population initiated
Implications:
- IRB may represent another chemoimmunotherapeutic option in RR CLL/SLL
View the original abstract on the ASH website.
